{
  "docId": "019de072-e9f7-73aa-b63d-f50108da815f",
  "docSlug": "8dc30a1d33d144ab07b1459d0ae0e445",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 43 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 43,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a matrix-like layout to map treatment lines against cancer types, emphasizing the 'replace' strategy in existing markets and 'broaden/expand' strategy in new markets.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de072-e9f7-73aa-b63d-f50108da815f/10",
  "deckHref": "/decks/019de072-e9f7-73aa-b63d-f50108da815f",
  "deckJsonHref": "/decks/019de072-e9f7-73aa-b63d-f50108da815f.json",
  "deckAnchorHref": "/decks/019de072-e9f7-73aa-b63d-f50108da815f#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.82,
        "x": 0.15,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Matrix of cancer types vs treatment lines",
      "attrs": null,
      "subkind": "matrix-nxn",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ebdfba35-2d93-496f-af15-25b930ef9329",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.03,
        "y": 0.93
      },
      "kind": "disclaimer",
      "text": "1. Ineligible to endocrine therapy and in those who are endocrine refractory/resistant. HER2-positive = human epidermal growth factor receptor 2 positive; HER2-low = human epidermal growth factor receptor 2 low; HR+ = hormone-receptor positive; HR- = hormone-receptor negative; CDK4/6i = cyclin-dependent kinase 4/6 inhibitor; T-DM1 = trastuzumab emtansine; IO = immuno-oncology; TNBC = triple negative breast cancer; NSCLC = non-small cell lung cancer; CRC = colorectal cancer.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "513feaf0-7566-463b-9b58-3826f29cc5b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.55,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Leading data in breast and expanding into gastric, lung and colorectal",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bfd1ad2d-ea08-4567-a6a9-2dd19c5e52cb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.55,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Enhertu has demonstrated efficacy across multiple cancer types",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "15e0e755-e52d-46e2-9660-b3d50c030b92",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "matrix-nxn",
      "slug": null,
      "matchId": "4a596e5d-a00d-461a-bf89-f5b4313e7942",
      "evidence": "The slide organizes clinical strategy across two axes: cancer type (rows) and treatment line (columns).",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 10,
      "from": 10,
      "beatId": "ff918123-29e9-496b-9821-6a703a7a14d1",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Roadmap",
      "beatSlug": null,
      "evidence": "The roadmap for Enhertu is presented on page 10",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}